Share Article

Renal denervation is a minimally invasive vascular procedure used to treat uncontrolled hypertension that offers several potential patient benefits over drug therapy.

Symple Surgical Inc. DirectAblate™ device platform

Hypertension is a worldwide medical and economic burden.

Flagstaff, Arizona (PRWEB)August 30, 2016

Symple Surgical Inc. (“SSI”) announced today the signing of a development agreement with a confidential strategic partner whose long standing market leadership position in endovascular device therapies makes it an ideal partner to continue development of novel microwave ablation technologies. As part of this agreement both parties will explore technological synergies and continue to develop pre-clinical evidence from SSI’s DirectAblate™ device platform.

Renal denervation is a minimally invasive vascular procedure used to treat uncontrolled hypertension that offers several potential patient benefits over drug therapy. The market is predicted to grow significantly due to the surge in global hypertension rates. There are several approved, carefully designed clinical trials in the US, EU and Asia focused on moving the field of sympathetic nerve modulation forward.

Daniel J. Kasprzyk, President & CEO commented: “We are very confident in the novel microwave ablation technology that has been developed at SSI with our talented and dedicated engineering team. We place enormous value on this strategic development partnership, which should rapidly advance our platform to achieve human clinical evidence. SSI has remained steadfast in our pursuit of next generation ablation technology to provide controlled circumferential ablation, thermal depth control, intimal/media vessel protection, and novel procedural ablation feedback all built into a single device. The DirectAblate™ and InSite™ Renal Denervation Technologies will provide the market with the next generation solution.”

SSI has raised roughly $3.0M in angel round financing since 2012 and has advanced its novel antennae based microwave ablation technology for multiple possible applications, including treatment of Barrett’s esophagus and pulmonary hypertension, among other ablation opportunities.

Dr. Gary M. Ansel, MD, FACC, observes: “Hypertension is a worldwide medical and economic burden. Renal Sympathetic Denervation is a unique therapy that has demonstrated benefits in patients that are not well treated with medical therapy alone. The “SSI” microwave system is evaluating a unique energy source in an effort to improve safety and efficacy to the normal vessel wall while providing a high level of success in controlling hypertension. I am excited to evaluate the clinical potential of this unique approach.”

About Symple Surgical Inc.
Symple Surgical, Inc. is a privately-held early stage medical device company with engineering and product development offices in Flagstaff, AZ and Sacramento, CA. Symple Surgical is focused on developing a medical device platform to help millions of patients living with hypertension symptoms through renal sympathetic denervation by delivering controlled microwave energy at the location of the sympathetic nerves while minimizing thermal exposure to non-targeted areas.